Go to deals
Healthcare

ANGLE has completed a fundraising

October 2020 — ANGLE Plc has raised funds to develop the company.

ANGLE, through its subsidiaries, engages in providing products in cancer diagnostics and foetal health. Its main product is the Parsortix cell separation system, which can capture very rare cells from the blood.

Our role in the transaction

Oaklins Cavendish’s sister firm finnCap, based in the UK, in its role as nominated advisor and joint broker, lead the fundraising process from start to finish. During this process, the team initiated and advised on many aspects, including, among others, securing pre-commitments from cornerstone investors, deal structuring and the fundraise pricing and sizing.

Talk to the deal team

Peter Gray

Partner
London, United Kingdom
Oaklins Cavendish

Related deals

Life & Mobility has attracted investor Bolster Investment Partners
Private Equity | Healthcare

Life & Mobility has attracted investor Bolster Investment Partners

Life & Mobility, a leading developer and manufacturer of premium mobility and rehabilitation solutions, has welcomed Bolster Investment Partners as a new shareholder. The partnership provides Life & Mobility with a strong long-term partner to support the company’s next phase of growth, with a continued focus on product innovation, strengthening its leading market position and further international expansion. The company’s mission remains to enhance the mobility, independence and quality of life of end users through innovative, sustainable and circular mobility solutions designed for multiple life cycles.  

Learn more
Synergia and Bolster have secured acquisition financing for Life & Mobility
Private Equity | Healthcare

Synergia and Bolster have secured acquisition financing for Life & Mobility

Synergia Capital Partners and Bolster Investment Partners have partnered with Life & Mobility, a leading Dutch developer and manufacturer of premium mobility and rehabilitation solutions. The partnership marks an important next step in Life & Mobility’s growth trajectory, focused on further international expansion, continued product innovation and strengthening its leading market position.

Learn more
7BidCo has completed the sell-out procedure for the shares of STAR7
Private Equity | Other Industries

7BidCo has completed the sell-out procedure for the shares of STAR7

7BidCo S.p.A. has completed the sell-out procedure for 8.5% of STAR7 S.p.A.’s shares.

Learn more